Table 2.
Comparison of non‐fasting plasma low‐density lipoprotein cholesterol by treatment group
| Placebo | Simvastatin | |||||||
|---|---|---|---|---|---|---|---|---|
| n | LDL (mmol/l)* | n | LDL (mmol/l)* | Unadjusted mean difference | P ‡ | Adjusted mean difference† | P ‡ | |
| Intention‐to‐treat | ||||||||
| 3‐month visit | 13 | 3·00(0·54) | 15 | 2·20(0·85) | −0·80 (−1·36 to −0·24) | 0·007 | –0·83 (–1·40 to –0·22) | 0·009 |
| 6‐month visit | 10 | 3·09(0·63) | 14 | 2·14(1·01) | −0·95 (−1·71 to −0·20) | 0·016 | –1·23 (–1·85 to –0·40) | 0·004 |
| 9‐month visit | 8 | 2·89(0·61) | 12 | 2·17(0·74) | −0·72 (−1·39 to −0·05) | 0·036 | –0·79 (–1·47 to –0·11) | 0·025 |
| 12‐month visit | 4 | 3·00(0·28) | 6 | 2·07(0·47) | −0·93 (−1·54 to −0·33) | 0·008 | –0·99 (–1·58 to –0·40) | 0·007 |
| Per‐protocol | ||||||||
| 3‐month visit | 7 | 3·00(0·60) | 9 | 2·46(0·96) | −0·53 (–1·42 to 0·36) | 0·224 | –0·49 (–1·47 to 0·49) | 0·300 |
| 6‐month visit | 8 | 3·09(0·66) | 12 | 2·09(1·09) | –1·00 (–1·91 to –0·09) | 0·034 | –1·16 (–2·01 to –0·32) | 0·010 |
| 9‐month visit | 7 | 2·86(0·66) | 12 | 2·17(0·74) | –0·69 (–1·41 to 0·03) | 0·058 | –0·74 (–1·47 to –0·00) | 0·049 |
| 12‐month visit | 3 | 3·07(0·31) | 5 | 2·02(0·51) | –1·05 (–1·85 to –0·24) | 0·019 | –1·16 (–1·96 to –0·35) | 0·016 |
Values in parentheses are 95 per cent confidence intervals unless indicated otherwise;
*
values are mean(s.d.). Analysis by ANCOVA.
†
Adjusted for screening values. A negative difference implies that patients taking simvastatin have a lower low‐density lipoprotein (LDL) cholesterol level than those on placebo.
‡
Student's t‐test and ¶ calculated by ANCOVA.